RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Finlay, James ^a   Roberts, Cai M ^a   Lowe, Gina ^a   Loeza, Joana ^b   Rossi, John J ^a   Glackin, Carlotta A ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; POLYAMIDOAMINE; RNA; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; NUCLEAR PROTEIN; PAMAM STARBURST; TRANSCRIPTION FACTOR TWIST; TWIST1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BREAST CANCER CELL LINE; BREAST METASTASIS; CANCER CELL; CELL ASSAY; CELL INVASION; CELL MIGRATION; COMPLEX FORMATION; CONTROLLED STUDY; DRUG DISTRIBUTION; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE DELIVERY SYSTEM; GENE SILENCING; GENE TARGETING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; TRANSWELL ASSAY; TRIPLE NEGATIVE BREAST CANCER; TUMOR XENOGRAFT; WOUND HEALING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; NEOPLASM METASTASIS; PROCEDURES; TUMOR CELL LINE; TUMOR INVASION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DENDRIMERS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NUCLEAR PROTEINS; RNA; RNA, SMALL INTERFERING; TRANSCRIPTION FACTORS; TRANSFECTION; TWIST TRANSCRIPTION FACTOR;

EID: 84924111260     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/382745     Document Type: Article

References (65)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal, "Cancer statistics, 2014," CA Cancer Journal for Clinicians, vol. 64, no. 1, pp. 9-29, 2014.
2. O. Hussein and S. V. Komarova, "Breast cancer at bone metastatic sites: recent discoveries and treatment targets," Journal of Cell Communication and Signaling, vol. 5, no. 2, pp. 85-99, 2011.
3. N. U. Lin, E. Claus, J. Sohl, A. R. Razzak, A. Arnaout, and E. P. Winer, "Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases," Cancer, vol. 113, no. 10, pp. 2638-2645, 2008.
4. F. Vesuna, P. van Diest, J. H. Chen, and V. Raman, "Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer," Biochemical and Biophysical Research Communications, vol. 367, no. 2, pp. 235-241, 2008.
5. B. G. Hollier, K. Evans, and S. A. Mani, "The epithelial-tomesenchymal transition and cancer stem cells: a coalition against cancer therapies," Journal of Mammary Gland Biology and Neoplasia, vol. 14, no. 1, pp. 29-43, 2009.
6. D. Kong, Y. Li, Z. Wang, and F.H. Sarkar, "Cancer stemcells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?" Cancers, vol. 3, no. 1, pp. 716-729, 2011.
7. N. Takebe, R. Q. Warren, and S. P. Ivy, "Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition," Breast Cancer Research, vol. 13, no. 3, article 211, 2011.
8. O. Watanabe, H. Imamura, T. Shimizu et al., "Expression of twist and wnt in human breast cancer," Anticancer Research, vol. 24, no. 6, pp. 3851-3856, 2004.
9. A. E. Vernon and C. LaBonne, "Tumor metastasis: a new twist on epithelial-mesenchymal transitions," Current Biology, vol. 14, no. 17, pp. R719-R721, 2004.
10. F. Vesuna, A. Lisok, B. Kimble, and V. Raman, "Twistmodulates breast cancer stem cells by transcriptional regulation of CD24 expression," Neoplasia, vol. 11, no. 12, pp. 1318-1328, 2009.
11. M.-Y. Feng, K. Wang, H.-T. Song et al., "Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells," Clinical and Experimental Metastasis, vol. 26, no. 8, pp. 1013-1023, 2009.
12. R. Maestro, A. P. Dei Tos, Y. Hamamori et al., "Twist is a potential oncogene that inhibits apoptosis," Genes and Development, vol. 13, no. 17, pp. 2207-2217, 1999.
13. J. Fu, L. Zhang, T. He et al., "TWIST represses estrogen receptoralpha expression by recruiting the NuRD protein complex in breast cancer cells," International Journal of Biological Sciences, vol. 8, no. 4, pp. 522-532, 2012.
14. F. Vesuna, A. Lisok, B. Kimble et al., "Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha," Oncogene, vol. 31, no. 27, pp. 3223-3234, 2012.
15. Y. Chen, L. Li, J. Zeng et al., "Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating Pglycoprotein," Chemotherapy, vol. 58, no. 4, pp. 264-272, 2012.
16. M. C. Elias, K. R. Tozer, J. R. Silber et al., "TWIST is expressed in human gliomas and promotes invasion," Neoplasia, vol. 7, no. 9, pp. 824-837, 2005.
17. N. Matsuo, H. Shiraha, T. Fujikawa et al., "Twist expression promotes migration and invasion in hepatocellular carcinoma," BMC Cancer, vol. 9, article 240, 2009.
18. H.-F. Yuen, Y.-P. Chan, M. L.-Y. Wong et al., "Upregulation of Twist in oesophageal squamous cell carcinoma is associated with neoplastic transformation and distant metastasis," Journal of Clinical Pathology, vol. 60, no. 5, pp. 510-514, 2007.
19. H.-F. Yuen, C.-W. Chua, Y.-P. Chan, Y.-C. Wong, X. Wang, and K.-W. Chan, "Significance of TWIST and E-cadherin expression in the metastatic progression of prostatic cancer," Histopathology, vol. 50, no. 5, pp. 648-658, 2007.
20. T.A. Martin, A. Goyal, G. Watkins, and W. G. Jiang, "Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer," Annals of Surgical Oncology, vol. 12, no. 6, pp. 488-496, 2005.
21. J. G. H. van Nes, E. M. de Kruijf, H. Putter et al., "Coexpression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients," Breast Cancer Research and Treatment, vol. 133, no. 1, pp. 49-59, 2012.
22. J. Yang, S. A. Mani, J.L. Donaher et al., "Twist, amaster regulator of morphogenesis, plays an essential role in tumor metastasis," Cell, vol. 117, no. 7, pp. 927-939, 2004.
23. M. A. Khan, H.-C. Chen, D. Zhang, and J. Fu, "Twist: a molecular target in cancer therapeutics," Tumor Biology, vol. 34, no. 5, pp. 2497-2506, 2013.
24. A. Fire, S. Xu, M. K. Montgomery, S. A. Kostas, S. E. Driver, and C. C. Mello, "Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans," Nature, vol. 391, no. 6669, pp. 806-811, 1998.
25. K. A. Whitehead, R. Langer, and D. G. Anderson, "Knocking down barriers: advances in siRNA delivery," Nature Reviews Drug Discovery, vol. 8, no. 2, pp. 129-138, 2009.
26. A. J. Hamilton and D. C. Baulcombe, "A species of small antisense RNA in posttranscriptional gene silencing in plants," Science, vol. 286, no. 5441, pp. 950-952, 1999.
27. P. Guo, O. Coban, N. M. Snead et al., "Engineering RNA for targeted siRNA delivery and medical application," Advanced Drug Delivery Reviews, vol. 62, no. 6, pp. 650-666, 2010.
28. L. Aagaard and J. J. Rossi, "RNAi therapeutics: principles, prospects and challenges," Advanced Drug Delivery Reviews, vol. 59, no. 2-3, pp. 75-86, 2007.
29. M. A. Behlke, "Progress towards in vivo use of siRNAs," Molecular Therapy, vol. 13, no. 4, pp. 644-670, 2006.
30. K. Gavrilov and W. M. Saltzman, "Therapeutic siRNA: principles, challenges, and strategies," The Yale Journal of Biology and Medicine, vol. 85, no. 2, pp. 187-200, 2012.
31. N. M. Snead and J. J. Rossi, "Biogenesis and function of endogenous and exogenous siRNAs," Wiley Interdisciplinary Reviews: RNA, vol. 1, no. 1, pp. 117-131, 2010.
32. D. Castanotto and J. J. Rossi, "The promises and pitfalls of RNAinterference-based therapeutics," Nature, vol. 457, no. 7228, pp. 426-433, 2009.
33. J. Wang, Z. Lu, M. G. Wientjes, and J. L.-S. Au, "Delivery of siRNA therapeutics: barriers and carriers," The AAPS Journal, vol. 12, no. 4, pp. 492-503, 2010.
34. S. David, B. Pitard, J.-P. Benoît, and C. Passirani, "Non-viral nanosystems for systemic siRNA delivery," Pharmacological Research, vol. 62, no. 2, pp. 100-114, 2010.
35. C. Foged, "siRNA delivery with lipid-based systems: promises and pitfalls," Current Topics in Medicinal Chemistry, vol. 12, no. 2, pp. 97-107, 2012.
36. Y. Tang, Y.-B. Li, B. Wang et al., "Efficient in vitro siRNA delivery and intramuscular gene silencing using PEG-modified PAMAM dendrimers," Molecular Pharmaceutics, vol. 9, no. 6, pp. 1812-1821, 2012.
37. J. Zhou, C. P. Neff, X. Liu et al., "Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice," Molecular Therapy, vol. 19, no. 12, pp. 2228-2238, 2011.
38. T. Yu, X. Liu, A.-L. Bolcato-Bellemin et al., "An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in Vitro and in vivo," Angewandte Chemie International Edition, vol. 51, no. 34, pp. 8478-8484, 2012.
39. X. Liu, J. Zhou, T. Yu et al., "Adaptive amphiphilic dendrimerbased nanoassemblies as robust and versatile siRNA delivery systems," Angewandte Chemie-International Edition, vol. 53, no. 44, pp. 11822-11827, 2014.
40. S. Li, S. E. Kendall, R. Raices et al., "TWIST1 associates with NF-κB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production," BMC Biology, vol. 10, article 73, 2012.
41. + cytolytic T cells," Cancer Research, vol. 69, no. 23, pp. 8886-8893, 2009.
42. S. Samineni, C. Glackin, and J. E. Shively, "Role of CEACAM1, ECM, and mesenchymal stem cells in an orthotopic model of human breast cancer," International Journal of Breast Cancer, vol. 2011, Article ID 381080, 10 pages, 2011.
43. C.-C. Liang, A. Y. Park, and J.-L. Guan, "In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro," Nature Protocols, vol. 2, no. 2, pp. 329-333, 2007.
44. Y. Teng and X. Li, "The roles of HLH transcription factors in epithelial mesenchymal transition and multiple molecular mechanisms," Clinical and Experimental Metastasis, vol. 31, no. 3, pp. 367-377, 2014.
45. D. Ouyang, H. Zhang, H. S. Parekh, and S. C. Smith, "The effect of pH on PAMAM dendrimer-siRNA complexation-endosomal considerations as determined by molecular dynamics simulation," Biophysical Chemistry, vol. 158, no. 2-3, pp. 126-133, 2011.
46. R. V. Benjaminsen, M. A. Mattebjerg, J. R. Henriksen, S. M. Moghimi, and T. L. Andresen, "The possible 'proton sponge' effect of polyethylenimine (PEI) does not include change in lysosomal pH," Molecular Therapy, vol. 21, no. 1, pp. 149-157, 2013.
47. C.-H. Zhang, G.-L. Xu, W.-D. Jia et al., "Activation of STAT3 signal pathway correlates with twist and E-cadherin expression in hepatocellular carcinoma and their clinical significance," The Journal of Surgical Research, vol. 174, no. 1, pp. 120-129, 2012.
48. C. Li, Y. Ren, X. Jia et al., "Twist overexpression promoted epithelial-to-mesenchymal transition of human peritoneal mesothelial cells under high glucose," Nephrology Dialysis Transplantation, vol. 27, no. 11, pp. 4119-4124, 2012.
49. H. Kobayashi, R. Watanabe, and P. L. Choyke, "Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?" Theranostics, vol. 4, no. 1, pp. 81-89, 2014.
50. K. Greish, "Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting," Methods in Molecular Biology, vol. 624, pp. 25-37, 2010.
51. S. Biswas and V. P. Torchilin, "Dendrimers for siRNA delivery," Pharmaceuticals, vol. 6, no. 2, pp. 161-183, 2013.
52. W. Kress, C. Schropp, G. Lieb et al., "Saethre-Chotzen syndrome caused by TWIST 1 gene mutations: functional differentiation from Muenke coronal synostosis syndrome," European Journal of Human Genetics, vol. 14, no. 1, pp. 39-48, 2006.
53. V. El Ghouzzi, E. Lajeunie, M. Le Merrer et al., "Mutations within or upstream of the basic helix-loop-helix domain of the TWIST gene are specific to Saethre-Chotzen syndrome," European Journal of Human Genetics, vol. 7, no. 1, pp. 27-33, 1999.
54. P. Bialek, B. Kern, X. Yang et al., "A twist code determines the onset of osteoblast differentiation," Developmental Cell, vol. 6, no. 3, pp. 423-435, 2004.
55. K. Soo, M. P. O'Rourke, P.-L. Khoo et al., "Twist function is required for the morphogenesis of the cephalic neural tube and the differentiation of the cranial neural crest cells in the mouse embryo," Developmental Biology, vol. 247, no. 2, pp. 251-270, 2002.
56. S. Isenmann, A. Arthur, A. C. W. Zannettino et al., "TWIST family of basic helix-loop-helix transcription factors mediate human mesenchymal stem cell growth and commitment," Stem Cells, vol. 27, no. 10, pp. 2457-2468, 2009.
57. X. Wang, M. T. Ling, X.-Y. Guan et al., "Identification of a novel function of Twist, a bHLH protein, in the development of acquired taxol resistance in human cancer cells," Oncogene, vol. 23, no. 2, pp. 474-482, 2004.
58. Q.-Q. Li, J.-D. Xu, W.-J. Wang et al., "Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells," Clinical Cancer Research, vol. 15, no. 8, pp. 2657-2665, 2009.
59. Y. Mironchik, P. T. Winnard Jr., F. Vesuna et al., "Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer," Cancer Research, vol. 65, no. 23, pp. 10801-10809, 2005.
60. H. Meng, M. Xue, T. Xia et al., "Use of size and a copolymer design feature to improve the biodistribution and the enhanced permeability and retention effect of doxorubicin-loaded mesoporous silica nanoparticles in amurine xenograft tumormodel," ACS Nano, vol. 5, no. 5, pp. 4131-4144, 2011.
61. J. Lu, M. Liong, Z. Li, J. I. Zink, and F. Tamanoi, "Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals," Small, vol. 6, no. 16, pp. 1794-1805, 2010.
62. H. Meng, M. Xue, T. Xia et al., "Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pHsensitive nanovalves," Journal of the American Chemical Society, vol. 132, no. 36, pp. 12690-12697, 2010.
63. J. Zhang, P. Wang, F. Wu et al., "Aberrant expression of the transcriptional factor Twist1 promotes invasiveness in ALKpositive anaplastic large cell lymphoma," Cellular Signalling, vol. 24, no. 4, pp. 852-858, 2012.
64. W. K. Kwok, M.-T. Ling, T.-W. Lee et al., "Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target," Cancer Research, vol. 65, no. 12, pp. 5153-5162, 2005.
65. H. Wallerand, G. Robert, G. Pasticier et al., "The epithelialmesenchymal transition-inducing factor TWIST is an attractive target in advanced and/or metastatic bladder and prostate cancers," Urologic Oncology, vol. 28, no. 5, pp. 473-479, 2010.